{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:22Z","timestamp":1794047362240,"version":"4.8.0"},"reference-count":32,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy delays, dose reductions, and discontinuation. There is no FDA-approved agent available to manage CIT. This study retrospectively evaluated patients with CIT treated on institutional romiplostim treatment pathways at 4 U.S. centers. The primary outcome was achievement of a romiplostim response [median on-romiplostim platelet count (Plt) \u226575x109\/L and \u226530x109\/L above baseline]. Secondary outcomes included time to Plt\u2265100x109\/L and rates of the following: Plt&lt;100x109\/L, Plt&lt;75x109\/L, Plt&lt;50x109\/L, thrombocytosis, chemotherapy dose reduction\/treatment delay, platelet transfusion, bleeding, and thromboembolism. Multivariable regression was used to identify predictors of romiplostim non-response and compare weekly dosing with intracycle\/intermittent dosing. 173 patients (153 solid tumor, 20 lymphoma or myeloma) were treated, with 170 (98%) receiving a median of 4 (range, 1-36) additional chemotherapy cycles on romiplostim. Romiplostim was effective in solid tumor patients: 71% of patients achieved a romiplostim response, 79% avoided chemotherapy dose reductions\/treatment delays and 89% avoided platelet transfusions. Median per-patient Plt on romiplostim was significantly higher than baseline (116x109\/L vs. 60x109\/L, P&lt;0.001). Bone marrow tumor invasion, prior pelvic irradiation, and prior temozolomide predicted romiplostim non-response. Bleeding rates were lower than historical CIT cohorts and thrombosis rates were not elevated. Weekly dosing was superior to intracycle dosing with higher response rates and less chemotherapy dose reductions\/treatment delays (IRR 3.00, 95% CI 1.30-6.91, P=0.010) or bleeding (IRR 4.84, 95% CI 1.18-19.89, P=0.029). Blunted response (10% response rate) was seen in non-myeloid hematologic malignancy patients with bone marrow involvement. In conclusion, romiplostim was safe and effective for CIT in most solid tumor patients.<\/jats:p>","DOI":"10.3324\/haematol.2020.251900","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T15:05:24Z","timestamp":1591283124000},"page":"1148-1157","source":"Crossref","is-referenced-by-count":95,"title":["A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies"],"prefix":"10.3324","volume":"106","author":[{"family":"Hanny Al-Samkari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Aric D. Parnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Katayoon Goodarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"James I. Weitzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jean M. Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"David J. Kuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,6,4]]},"reference":[{"key":"24376","unstructured":"Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015; 29(4):282-294."},{"key":"24377","doi-asserted-by":"crossref","unstructured":"Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009; 31(Pt 2):2416-2432.","DOI":"10.1016\/j.clinthera.2009.11.020"},{"key":"24378","doi-asserted-by":"crossref","unstructured":"Denduluri N, Patt DA, Wang Y. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw. 2015; 13(11):1383-1393.","DOI":"10.6004\/jnccn.2015.0166"},{"key":"24379","doi-asserted-by":"crossref","unstructured":"Elting LS, Rubenstein EB, Martin CG. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. 2001; 19(4):1137-1146.","DOI":"10.1200\/JCO.2001.19.4.1137"},{"key":"24380","doi-asserted-by":"crossref","unstructured":"Moskowitz CH, Hamlin PA, Gabrilove J. Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol. 2007; 18(11):1842-1850.","DOI":"10.1093\/annonc\/mdm341"},{"key":"24381","doi-asserted-by":"crossref","unstructured":"Aspinall SL, Good CB, Zhao X. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans. BMC Cancer. 2015; 15:62.","DOI":"10.1186\/s12885-015-1038-y"},{"key":"24382","doi-asserted-by":"crossref","unstructured":"Havrilesky LJ, Reiner M, Morrow PK, Watson H, Crawford J. A review of relative dose intensity and survival in patients with metastatic solid tumors. Crit Rev Oncol Hematol. 2015; 93(3):203-210.","DOI":"10.1016\/j.critrevonc.2014.10.006"},{"key":"24383","doi-asserted-by":"crossref","unstructured":"Hanna RK, Poniewierski MS, Laskey RA. Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2013; 129(1):74-80.","DOI":"10.1016\/j.ygyno.2012.12.017"},{"key":"24384","doi-asserted-by":"crossref","unstructured":"Kuter DJ, Rummel M, Boccia R. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010; 363(20):1889-1899.","DOI":"10.1056\/NEJMoa1002625"},{"key":"24385","doi-asserted-by":"crossref","unstructured":"Townsley DM, Scheinberg P, Winkler T. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017; 376(16):1540-1550.","DOI":"10.1056\/NEJMoa1613878"},{"key":"24386","doi-asserted-by":"crossref","unstructured":"Afdhal NH, Dusheiko GM, Giannini EG. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014; 146(2):442-452e441.","DOI":"10.1053\/j.gastro.2013.10.012"},{"key":"24387","doi-asserted-by":"crossref","unstructured":"Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. Romiplostim for the management of perioperative thrombocytopenia. Br J Haematol. 2018; 182(1):106-113.","DOI":"10.1111\/bjh.15280"},{"key":"24388","doi-asserted-by":"crossref","unstructured":"Terrault N, Chen YC, Izumi N. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018; 155(3):705-718.","DOI":"10.1053\/j.gastro.2018.05.025"},{"key":"24389","doi-asserted-by":"crossref","unstructured":"Tateishi R, Seike M, Kudo M. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation. J Gastroenterol. 2018; 54(2):171-181.","DOI":"10.1007\/s00535-018-1499-2"},{"key":"24390","doi-asserted-by":"crossref","unstructured":"Kumagai Y, Fujita T, Ozaki M. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol. 2007; 47(12):1489-1497.","DOI":"10.1177\/0091270007306563"},{"key":"24391","doi-asserted-by":"crossref","unstructured":"Jenkins JM, Williams D, Deng Y. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood. 2007; 109(11):4739-4741.","DOI":"10.1182\/blood-2006-11-057968"},{"key":"24392","doi-asserted-by":"crossref","unstructured":"Nomoto M, Pastino G, Rege B, Aluri J, Ferry J, Han D. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev. 2018; 7(2):188-195.","DOI":"10.1002\/cpdd.349"},{"key":"24393","doi-asserted-by":"crossref","unstructured":"Parameswaran R, Lunning M, Mantha S. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014; 22(5):1217-1222.","DOI":"10.1007\/s00520-013-2074-2"},{"key":"24394","doi-asserted-by":"crossref","unstructured":"Miao J, Leblebjian H, Scullion B, Parnes A. A single center experience with romiplostim for the management of chemotherapy- induced thrombocytopenia. Am J Hematol. 2018; 93(4):E86-E88.","DOI":"10.1002\/ajh.25022"},{"key":"24395","doi-asserted-by":"crossref","unstructured":"Al-Samkari H, Marshall AL, Goodarzi K, Kuter DJ. The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors. Haematologica. 2018; 103(4):e169-e172.","DOI":"10.3324\/haematol.2017.180166"},{"key":"24396","doi-asserted-by":"crossref","unstructured":"Soff GA, Miao Y, Bendheim G. Romiplostim treatment of chemotherapyinduced thrombocytopenia. J Clin Oncol. 2019; 37(31):2892-2898.","DOI":"10.1200\/JCO.18.01931"},{"key":"24397","unstructured":"Tepler I, Elias L, Smith JW 2nd. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996; 87(9):3607-3614."},{"key":"24398","doi-asserted-by":"crossref","unstructured":"Vadhan-Raj S, Verschraegen CF, Bueso- Ramos C. Recombinant human thrombopoietin attenuates carboplatininduced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med. 2000; 132(5):364-368.","DOI":"10.7326\/0003-4819-132-5-200003070-00005"},{"key":"24399","doi-asserted-by":"crossref","unstructured":"Basser RL, Underhill C, Davis I. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol. 2000; 18(15):2852-2861.","DOI":"10.1200\/JCO.2000.18.15.2852"},{"key":"24400","doi-asserted-by":"crossref","unstructured":"Neumann TA, Foote M. Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis. Cytokines Cell Mol Ther. 2000; 6(1):47-56.","DOI":"10.1080\/13684730050515912"},{"key":"24401","unstructured":"Consensus Committee of Chemotherapy Induced Thrombocytopenia CSoCO. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)]. Zhonghua Zhong Liu Za Zhi. 2018; 40(9):714-720."},{"key":"24402","doi-asserted-by":"crossref","unstructured":"Demeter J, Istenes I, Fodor A. Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. Pathol Oncol Res. 2011; 17(1):141-143.","DOI":"10.1007\/s12253-010-9276-4"},{"key":"24403","doi-asserted-by":"crossref","unstructured":"Villano JL, Letarte N, Yu JM, Abdur S, Bressler LR. Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol. 2012; 69(1):107-113.","DOI":"10.1007\/s00280-011-1679-8"},{"key":"24404","doi-asserted-by":"crossref","unstructured":"Wun T, White RH. Epidemiology of cancerrelated venous thromboembolism. Best Pract Res Clin Haematol. 2009; 22(1):9-23.","DOI":"10.1016\/j.beha.2008.12.001"},{"key":"24405","doi-asserted-by":"crossref","unstructured":"Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119(3):648-655.","DOI":"10.1002\/cncr.27772"},{"key":"24406","doi-asserted-by":"crossref","unstructured":"Haas SK, Freund M, Heigener D. Lowmolecular- weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer. Clin Appl Thromb Hemost. 2012; 18(2):159-165.","DOI":"10.1177\/1076029611433769"},{"key":"24407","doi-asserted-by":"crossref","unstructured":"Carrier M, Abou-Nassar K, Mallick R. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019; 380(8):711-719.","DOI":"10.1056\/NEJMoa1814468"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9776\/70949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9776\/70950","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9776\/70949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:17Z","timestamp":1794045437000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,4]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.251900","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,4]]}}}